Diffusion‐weighted MRI characteristics associated with prognostic pathological factors and recurrence risk in invasive ER+/HER2– breast cancers

Abstract

3 Technical Efficacy Stage 3 J. Magn. Reson. Imaging 2017.

Radiomic analysis of imaging heterogeneity in tumours and the surrounding parenchyma based on unsupervised decomposition of DCE-MRI for predicting molecular subtypes of breast cancer

“…First, this image decomposition method requires a relatively high temporal resolution, and applying this method to DCE-MR images is difficult with limited time-series data (i.e., less than three postcontrast series). Second, it would be of interest to perform intratumoural analysis based on other imaging modalities, such as DW-MRI [36] and T2-weighted imaging [37], to validate and extend this work. Third, the tumour sizes in this dataset were larger than 1 cm, and more studies with smaller tumour sizes should be performed.…”

Diffusion Kurtosis at 3.0T as an in vivo Imaging Marker for Breast Cancer Characterization: Correlation With Prognostic Factors

“…Breast cancers with high Ki-67 expression and high-grade tumors are associated with higher kurtosis and lower diffusivity coefficients, which is in good agreement with some recent literature. 23,33 As a biomarker of cell proliferation, the Ki-67 expression is a good predictive and prognostic marker widely used in clinical practice of breast cancer. 34,35 Its high expression is associated with a high risk of metastasis or recurrence, poor clinical or pathological response, and decreased survival.…”

Breast Cancer Radiogenomics: Current Status and Future Directions

“…For eligible women, chemotherapy could be avoided thus saving on patient morbidity and healthcare costs. As the most widely used assay in clinical practice, Oncotype Dx is also the most studied assay by radiogenomics investigators (9,10,20,(65)(66)(67)(68)(69)(70)(71)(72)(73). Although clinical decision making is based on Oncotype Dx subcategories of low, intermediate, and high, the Oncotype Dx score is a numerical value from 1 to 100 which allows for more precise outcome measures, as opposed to the four nominal molecular subtypes.…”

“…Although clinical decision making is based on Oncotype Dx subcategories of low, intermediate, and high, the Oncotype Dx score is a numerical value from 1 to 100 which allows for more precise outcome measures, as opposed to the four nominal molecular subtypes. Predictive models have found associations on MRI with DWI (65,67,69) and dynamic contrast-enhanced MRI sequences (66,68), but also associations with mammographic BI-RADS features (20) and texture analysis (73). Many of these predictive models include multiple input variables derived from imaging, clinical, and pathologic information.…”